In the SOPHIA trial [103], a phase III study, margetuximab, a novel monoclonal antibody targeting HER2, was compared to trastuzumab in patients with metastatic HER2-positive breast cancer who had previously progressed on other therapies, including Kadcyla. This evidence concerns the gene ERBB2 and breast cancer.